Glucotrack, Inc. (Nasdaq: GCTK) announces the completion of its strategic business combination with Lōkahi Therapeutics, establishing a publicly listed, capital-efficient platform for the identification, acquisition, and advancement of differentiated healthcare assets. Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.
Read the full article: Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform //
Source: https://www.globenewswire.com/news-release/2026/07/14/3327361/0/en/glucotrack-and-l%c5%8dkahi-therapeutics-complete-strategic-business-combination-establishing-l%c5%8dkahi-controlled-public-platform.html